Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

Por Walraven, Maudy, Homs, Marjolein Y. V., van der Veldt, Astrid A. M., Dekker, Henk, Koldenhof, Jose, Honeywell, Richard, Barendrecht, Arjan, Sebastian, Silvie A. E., Parr, Naomi, Koekman, Arnold C., Voest, Emile E., Roest, Mark, Korporaal, Suzanne J. A., Verheul, Henk M. W.
Publicado no Angiogenesis (2018)